Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.42 CAD 1.43%
Market Cap: 141.3m CAD

Cardiol Therapeutics Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cardiol Therapeutics Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Cardiol Therapeutics Inc
TSX:CRDL
Cash from Operating Activities
-CA$24.2m
CAGR 3-Years
-3%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Cash from Operating Activities
$1.5B
CAGR 3-Years
N/A
CAGR 5-Years
10%
CAGR 10-Years
-5%
Canopy Growth Corp
TSX:WEED
Cash from Operating Activities
-CA$88.4m
CAGR 3-Years
46%
CAGR 5-Years
34%
CAGR 10-Years
-23%
Sundial Growers Inc
NASDAQ:SNDL
Cash from Operating Activities
CA$69.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Cash from Operating Activities
$21.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Cash from Operating Activities
CA$35.6m
CAGR 3-Years
-4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cardiol Therapeutics Inc
Glance View

Market Cap
141.3m CAD
Industry
Pharmaceuticals

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

CRDL Intrinsic Value
2.81 CAD
Undervaluation 49%
Intrinsic Value
Price

See Also

What is Cardiol Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-24.2m CAD

Based on the financial report for Sep 30, 2025, Cardiol Therapeutics Inc's Cash from Operating Activities amounts to -24.2m CAD.

What is Cardiol Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-20%

Over the last year, the Cash from Operating Activities growth was 7%. The average annual Cash from Operating Activities growth rates for Cardiol Therapeutics Inc have been -3% over the past three years , -20% over the past five years .

Back to Top